Skip to product information
1 of 1

Invivo anti-Mouse CD223 Recombinant mAb

Invivo anti-Mouse CD223 Recombinant mAb

Catalog Number: S0B7084 Application: FCM Reactivity: Mouse Conjugation: Unconjugated Brand: Starter
Price:
Regular price $170 USD
Regular price Sale price $170 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rat
Antigen CD223
Synonyms Lymphocyte activation gene 3 protein; LAG-3; Activation-induced cytidine deaminase-linked autoimmunity protein (Aida); Lag3
Location Secreted, Cell membrane
Accession Q61790
Clone Number S-R624
Antibody Type Rat mAb
Isotype Rat IgG1,k
Application FCM
Reactivity Ms
Positive Sample Mouse CD3, CD28 antibody treated C57BL/6 mouse splenocytes
Purification Protein G
Concentration 5 mg/ml
Purity >95% (Determined by SDS-PAGE)
Endotoxin <1EU/mg
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative

Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;
-20 °C for 3 months under sterile conditions;
-80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.

Dilution


application dilution species
FCM 1:500 Ms

Background

CD223, also known as LAG-3 (lymphocyte activation gene-3), is a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily. It is expressed on the surface of activated T cells, regulatory T cells (Tregs), natural killer (NK) cells, and some other immune cells. Structurally, it is similar to CD4 and has a higher binding affinity to MHC class II molecules than CD4. LAG-3 primarily functions as an immune checkpoint receptor, negatively regulating T-cell activation, proliferation, and cytokine production. In cancer and chronic infections, elevated LAG-3 expression is associated with T cell exhaustion, limiting anti-tumor and antiviral responses. Due to its significant role in immune regulation, LAG-3 has become a promising target for cancer immunotherapy and the treatment of autoimmune disorders.

Picture

FC

Flow cytometric analysis of mouse CD223 expression on mouse CD3 and CD28 antibody treated C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes untreated (left panel) or treated 72h with anti-mouse CD3, CD28 (right panel) were labeled with Mouse CD223 antibody at 1/500 dilution (1 μg). Goat Anti-Rat IgG Alexa Fluor® 647 was used as the secondary antibody. Then cells were stained with CD3 - Alexa Fluor® 488 antibody. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.